Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women age 21 years or older~* Taking on average 5.0 mg/day prednisone or equivalent for at least 3 months prior to screening~Exclusion Criteria:~* Taking bisphosphonates within past 6 months~* More than 30 micrograms/day of estradiol or equivalent in past 3 months~* History of alcoholism or drug abuse in past year~* Pregnant women or nursing mothers

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Teriparatide 20 micrograms/day injection plus oral placebo, 36 months
- B (Type: ACTIVE_COMPARATOR): Alendronate 10 mg/day oral plus injection placebo, 36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).